Morgan Stanley maintains Monopar Therapeutics at Overweight, raises price target to $133 from $130
Morgan Stanley kept Monopar Therapeutics at Overweight, raising its price target to $133 from $130, suggesting an 84.7% upside from the Nov 13 close of $72.
How this was made

The 30-second read
Why it matters
The upgrade could attract short‑term buying, but investors should monitor upcoming clinical data releases.
Market read
Analyst upgrade provides a fresh catalyst for MNP, offering a modest trading opportunity.
What to watch
Potential dilution from future financing rounds and regulatory risk are not addressed in the upgrade.
Background
Morgan Stanley's rating upgrade follows its internal analysis of Monopar's pipeline and recent trial updates.
Market effects
May lift sentiment in the biotech sector as analysts show confidence in small‑cap therapeutics.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The price target increase may be premature if upcoming trial data disappoints.
Key entities
- companyMonopar Therapeutics
Biotech firm developing therapies for rare diseases.
- analyst_firmMorgan Stanley
Investment bank providing the rating and price target.
